用於治療Dry Mouth的藥物可能有助於預防肺癌

使用這種藥物,可以使吸煙者肺部細胞形態異常的損害,進一步發展的可能性降低

  2002年4月15日──4月10日在第93屆美國癌症研究學會年會上宣讀的一篇研究結果顯示,一種用於治療Dry Mouth的藥物,可以使吸煙者肺部的細胞形態異常的損害,發展為癌症的危險降低。

  第一作者溫哥華British Columbia大學的Stephen Lam醫師FRCPC,在一篇新聞稿中說:「即使人們在晚年戒煙,他們發生肺癌的危險也不會去除。」

  為了能夠找到一種肺癌的化學預防藥物,研究小組對101位有支氣管細胞形態異常的吸煙者或者曾經吸煙者,隨機進行anethole dithiolethione (ADT)25mg口服或者安慰劑治療,每日三次,治療6個月。主要的副作用為較輕微的消化道症狀,降低ADT的劑量或者停止使用這種藥物即可解決。

  支氣管鏡以及活檢的結果顯示,ADT治療組以前存在的細胞形態異常損害的進展以及新損害的出現率都比較低(8%,而安慰劑組為17%)。對每個樣本所有損傷的分析顯示,採用ADT治療組的進展率較低(32%,而安慰劑組為54%)。Lam認為對於一種治療措施來說,這個結果是更有顯著意義的,因為不同個體對於不同藥物的反應是不同的。

  作者寫道:「ADT可能是一種很有效的肺癌化學預防藥物,它的治療效果主要是基於其自由基清除以及誘導谷胱甘產生的特性。」

  這種藥物只在加拿大(Sialor)與歐洲(Sulfarlem)被批准用於治療Dry Mouth。

Drug Used for Dry Mouth May Help Prevent Lung Cancer

Dysplastic Lesions in Smokers' Lungs Less Likely to Progress

By Laurie Barclay, MD
WebMD Medical News

Reviewed by Gary D. Vogin, MD

April 12, 2002 -- A drug used to treat dry mouth may reduce the risk that dysplastic lesions in the lungs of smokers will progress to cancer, according to study presented April 10 at the 93rd Annual Meeting of the American Association for Cancer Research.

"When people give up smoking late in life, the risk of lung cancer does not go away," lead author Stephen Lam, MD, FRCPC, from the University of British Columbia in Vancouver, says in a news release.

Looking to find a chemopreventive agent for lung cancer, Lam's group randomized 101 current and former smokers with bronchial dysplasia to treatment with anethole dithiolethione (ADT) , 25 mg orally, or placebo, three times daily for six months. Adverse effects were mostly minor gastrointestinal symptoms that resolved when the dose was lowered or ADT was discontinued.

Bronchoscopy and biopsy revealed that the progression of pre-existing dysplastic lesions and the appearance of new lesions was lower in the ADT group (8% vs. 17% in the placebo group). Analysis of all the lesions in each subject suggested that the progression rate was lower with ADT (32% vs. 54% in the placebo group). According to Lam, this result is more significant for treatment, as individuals vary in their response to different agents.

"ADT is a potentially efficacious chemoprevention agent for lung cancer; its therapeutic effect is mainly based on its radical scavenger and glutathione-inducer properties," the authors write.

The drug currently is approved only in Canada (Sialor) and Europe (Sulfarlem) for treatment of dry mouth.

© 2002 WebMD Inc. All rights reserved.

    
相關報導
體適能較佳與某些癌症及死亡風險較低有關
2015/4/15 上午 10:28:31
終於有一種可以治療多數常見肺癌突變的療法
2012/6/20 下午 01:39:11
Afatinib使肺癌無惡化存活率加倍
2012/6/18 下午 05:19:27

上一頁
   1   2   3   4   5   6   7   8   9   10  




回上一頁